More recently, it has been shown that TAMs (CD11b+ MHC-II+) are capable of stripping anti-PD-1 bound to PD-1+ T cells by binding to the antibody Fc domain, abrogating the anti-tumor activity of this immune checkpoint inhibitor (17). This evidence concerns the gene ITGAM and neoplasm.